Global Ischemic Heart Disease Market Research and Forecast, 2018-2023
Ischemic heart disease, also known as CHD (coronary heart diseases) and CAD (coronary artery disease) is caused by defect and damage in the heart. Silent ischemia is one of the most prevailing ischemic diseases across the globe, caused by heart attack without prior warning. Moreover, the people having previous heart attacks or have diabetes are more prone to silent ischemia. Unhealthy dietary habits such as excessive consumption of alcohol & tobacco and lack of exercise increase the risk of ischemic heart diseases around the globe.
Various pivotal factors that are augmenting the ischemic heart disease market includes growing incidence and prevalence rate of hypertension, high cholesterol, diabetes, and obesity across the globe. Government funding for diagnosis, treatment and research and their initiative programs to increase the awareness toward disease is another major factor augmenting the growth of the market. However, the high costs of treatment coupled with the regular uncertainty seen in reimbursement policies can hamper the growth of the market. Opportunities that are expected to augment the market includes increasing awareness among people towards the heart diseases and improving healthcare system and healthcare spending in emerging economies.
A number of pipeline products by the major market player and various devices & drugs are expected to get Food and Drug Administration (FDA) approval which is also contributing in the growth of the market. For instance, in March 2017, FDA approved COBRA PzF NCS (NanoCoated coronary stent) system in order to improve coronary luminal diameter in certain patients with ischemic heart disease. In May 2018, the US FDA approved the use of replacement heart valve in paediatric patients during the treatment of heart diseases.
Global ischemic heart disease market is further analyzed on the basis of the geographical regions which are contributing significantly in the market. On the basis of geography, the market is divided into North America, Europe, Asia-Pacific, and Rest of the World. North America and Europe are expected to have a major market for ischemic heart disease during the forecast period. As per the Centers for Disease Control and Prevention (CDC), around 800,000 mortalities are reported due to ischemic disease every year in the US. As per the European Heart Network, around 3.9 million mortalities are reported due to CVDs (cardiovascular diseases) every year in Europe, wherein, nearly 1.8 million cases are reported in European Union. Asia-Pacific is projected to exhibit the fastest growth in the global ischemic heart diseases market during the forecast period. This is mainly owing to the rising prevalence of heart diseases and strokes and increasing awareness towards CAD.
Global ischemic heart disease market players such as Abbott Laboratories, Amgen Inc., Bayer AG, Sanofi SA, AstraZeneca PLC, Boston Scientific Corp., Genentech, Inc., Koninklijke Philips N.V., Medtronic, PLC, Merck KGaA, Siemens Healthcare Pvt. Ltd., and Stryker Corp. have been contributing significantly into the growth of the market. These companies are studied with different aspects in order to know about strategies opt by them in recent time. Major activities and business decisions taken by the market players of ischemic heart disease market includes merger & acquisition, product launch and so on.
Research Methodology
The market study of global ischemic heart diseases market is incorporated by extensive primary and secondary research conducted by a research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.
Secondary Sources Include:
Market Segmentation
Various pivotal factors that are augmenting the ischemic heart disease market includes growing incidence and prevalence rate of hypertension, high cholesterol, diabetes, and obesity across the globe. Government funding for diagnosis, treatment and research and their initiative programs to increase the awareness toward disease is another major factor augmenting the growth of the market. However, the high costs of treatment coupled with the regular uncertainty seen in reimbursement policies can hamper the growth of the market. Opportunities that are expected to augment the market includes increasing awareness among people towards the heart diseases and improving healthcare system and healthcare spending in emerging economies.
A number of pipeline products by the major market player and various devices & drugs are expected to get Food and Drug Administration (FDA) approval which is also contributing in the growth of the market. For instance, in March 2017, FDA approved COBRA PzF NCS (NanoCoated coronary stent) system in order to improve coronary luminal diameter in certain patients with ischemic heart disease. In May 2018, the US FDA approved the use of replacement heart valve in paediatric patients during the treatment of heart diseases.
Global ischemic heart disease market is further analyzed on the basis of the geographical regions which are contributing significantly in the market. On the basis of geography, the market is divided into North America, Europe, Asia-Pacific, and Rest of the World. North America and Europe are expected to have a major market for ischemic heart disease during the forecast period. As per the Centers for Disease Control and Prevention (CDC), around 800,000 mortalities are reported due to ischemic disease every year in the US. As per the European Heart Network, around 3.9 million mortalities are reported due to CVDs (cardiovascular diseases) every year in Europe, wherein, nearly 1.8 million cases are reported in European Union. Asia-Pacific is projected to exhibit the fastest growth in the global ischemic heart diseases market during the forecast period. This is mainly owing to the rising prevalence of heart diseases and strokes and increasing awareness towards CAD.
Global ischemic heart disease market players such as Abbott Laboratories, Amgen Inc., Bayer AG, Sanofi SA, AstraZeneca PLC, Boston Scientific Corp., Genentech, Inc., Koninklijke Philips N.V., Medtronic, PLC, Merck KGaA, Siemens Healthcare Pvt. Ltd., and Stryker Corp. have been contributing significantly into the growth of the market. These companies are studied with different aspects in order to know about strategies opt by them in recent time. Major activities and business decisions taken by the market players of ischemic heart disease market includes merger & acquisition, product launch and so on.
Research Methodology
The market study of global ischemic heart diseases market is incorporated by extensive primary and secondary research conducted by a research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.
Secondary Sources Include:
- Financial reports of companies involved in the market
- Authentic Public Databases such as the OECD, WHO, and others
- Whitepapers, research-papers and news blogs
- Company websites and their product catalog.
Market Segmentation
- Global Ischemic Heart Diseases Market Research and Analysis by Disease Type
- Global Ischemic Heart Diseases Market Research and Analysis by Diagnosis Method
- Global Ischemic Heart Diseases Market Research and Analysis by Treatment
- Comprehensive research methodology of global ischemic heart diseases
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global ischemic heart diseases market.
- Insights about market determinants which are stimulating the global ischemic heart diseases
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
CHAPTER 1. REPORT SUMMARY
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. Definition
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendation
2.2.3. Conclusion
2.3. Rules & Regulations
CHAPTER 3. MARKET DETERMINANT
3.1. Motivators
3.1.1. Rising Population with High Cholesterol, Diabetes, and Obesity
3.1.2. High Prevalence of CVD (Cardiovascular Disease)
3.1.3. Sedentary Lifestyle and Faulty Dietary Habits
3.1.4. Availability of Effective Surgical Treatments
3.2. Restraints
3.2.1. High Cost of Treatment
3.2.2. Uncertainty in Reimbursement Policies
3.3. Opportunities
3.3.1. Increasing Awareness Regarding Various Heart Diseases
3.3.2. Numerous Government Initiatives and Funding
3.3.3. Availability of Various Pipeline Products
CHAPTER 4. MARKET SEGMENTATION
4.1. Global Ischemic Heart Diseases Market by Disease Type
4.1.1. Angina
4.1.2. Myocardial Infarction
4.1.3. Ischemic Stroke
4.2. Global Ischemic Heart Diseases Market by Diagnosis Method
4.2.1. Electrocardiogram (ECG)
4.2.2. Echocardiogram
4.2.3. Chest X-Ray
4.2.4. Cardiac Catheterization
4.2.5. Coronary Angiogram
4.3. Global Ischemic Heart Diseases Market by Treatment
4.3.1. Medication
4.3.1.1. NSAID
4.3.1.2. Statins
4.3.1.3. Beta Blocker
4.3.1.4. Calcium Channel Blocker
4.3.1.5. ACE Inhibitors
4.3.1.6. Others (Organic Nitrates)
4.3.2. Surgery
4.3.2.1. Coronary Stent
4.3.2.2. Angioplasty
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. Key Strategy Analysis
5.2. Key Company Analysis
CHAPTER 6. REGIONAL ANALYSIS
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. RoE
6.3. Asia-Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World (RoW)
CHAPTER 7. COMPANY PROFILES
7.1. Abbott Laboratories
7.2. Amgen Inc.
7.3. AstraZeneca PLC
7.4. Bayer AG
7.5. Boston Scientific Corp.
7.6. Cardinal Health, Inc.
7.7. Daiichi Sankyo Co. Ltd.
7.8. Edwards Lifesciences Corp.
7.9. General Electric Co.
7.10. Genentech, Inc.
7.11. Koninklijke Philips N.V.
7.12. Lepu Medical Technology (Beijing) Co., Ltd.
7.13. Medtronic, PLC
7.14. Merck KGaA
7.15. Meril Life Science Pvt. Ltd.
7.16. Sanofi SA
7.17. Siemens Healthcare Pvt. Ltd.
7.18. Stryker Corp.
7.19. TERUMO CORP.
7.20. W. L. Gore & Associates, Inc.
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. Definition
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendation
2.2.3. Conclusion
2.3. Rules & Regulations
CHAPTER 3. MARKET DETERMINANT
3.1. Motivators
3.1.1. Rising Population with High Cholesterol, Diabetes, and Obesity
3.1.2. High Prevalence of CVD (Cardiovascular Disease)
3.1.3. Sedentary Lifestyle and Faulty Dietary Habits
3.1.4. Availability of Effective Surgical Treatments
3.2. Restraints
3.2.1. High Cost of Treatment
3.2.2. Uncertainty in Reimbursement Policies
3.3. Opportunities
3.3.1. Increasing Awareness Regarding Various Heart Diseases
3.3.2. Numerous Government Initiatives and Funding
3.3.3. Availability of Various Pipeline Products
CHAPTER 4. MARKET SEGMENTATION
4.1. Global Ischemic Heart Diseases Market by Disease Type
4.1.1. Angina
4.1.2. Myocardial Infarction
4.1.3. Ischemic Stroke
4.2. Global Ischemic Heart Diseases Market by Diagnosis Method
4.2.1. Electrocardiogram (ECG)
4.2.2. Echocardiogram
4.2.3. Chest X-Ray
4.2.4. Cardiac Catheterization
4.2.5. Coronary Angiogram
4.3. Global Ischemic Heart Diseases Market by Treatment
4.3.1. Medication
4.3.1.1. NSAID
4.3.1.2. Statins
4.3.1.3. Beta Blocker
4.3.1.4. Calcium Channel Blocker
4.3.1.5. ACE Inhibitors
4.3.1.6. Others (Organic Nitrates)
4.3.2. Surgery
4.3.2.1. Coronary Stent
4.3.2.2. Angioplasty
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. Key Strategy Analysis
5.2. Key Company Analysis
CHAPTER 6. REGIONAL ANALYSIS
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. RoE
6.3. Asia-Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World (RoW)
CHAPTER 7. COMPANY PROFILES
7.1. Abbott Laboratories
7.2. Amgen Inc.
7.3. AstraZeneca PLC
7.4. Bayer AG
7.5. Boston Scientific Corp.
7.6. Cardinal Health, Inc.
7.7. Daiichi Sankyo Co. Ltd.
7.8. Edwards Lifesciences Corp.
7.9. General Electric Co.
7.10. Genentech, Inc.
7.11. Koninklijke Philips N.V.
7.12. Lepu Medical Technology (Beijing) Co., Ltd.
7.13. Medtronic, PLC
7.14. Merck KGaA
7.15. Meril Life Science Pvt. Ltd.
7.16. Sanofi SA
7.17. Siemens Healthcare Pvt. Ltd.
7.18. Stryker Corp.
7.19. TERUMO CORP.
7.20. W. L. Gore & Associates, Inc.
LIST OF TABLES
TABLE # 1 GLOBAL ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023 ($ MILLION)
TABLE # 2 GLOBAL ANGINA MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 3 GLOBAL MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 4 GLOBAL ISCHEMIC STROKE MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 5 GLOBAL ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023 ($ MILLION)
TABLE # 6 GLOBAL ELECTROCARDIOGRAM (ECG) MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 7 GLOBAL ECHOCARDIOGRAM MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 8 GLOBAL CHEST X-RAY MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 9 GLOBAL CARDIAC CATHETERIZATION MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 10 GLOBAL CORONARY ANGIOGRAM MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 11 GLOBAL ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
TABLE # 12 GLOBAL DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 13 GLOBAL SURGERY MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 14 GLOBAL ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLION)
TABLE # 15 NORTH AMERICA ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023 ($ MILLION)
TABLE # 16 NORTH AMERICA ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023 ($ MILLION)
TABLE # 17 NORTH AMERICA ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
TABLE # 18 NORTH AMERICA ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 19 EUROPE ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023 ($ MILLION)
TABLE # 20 EUROPE ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023 ($ MILLION)
TABLE # 21 EUROPE ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
TABLE # 22 EUROPE ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 23 ASIA-PACIFIC ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023 ($ MILLION)
TABLE # 24 ASIA-PACIFIC ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023 ($ MILLION)
TABLE # 25 ASIA-PACIFIC ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
TABLE # 26 ASIA-PACIFIC ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 27 ROW ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023 ($ MILLION)
TABLE # 28 ROW ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023 ($ MILLION)
TABLE # 29 ROW ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
TABLE # 1 GLOBAL ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023 ($ MILLION)
TABLE # 2 GLOBAL ANGINA MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 3 GLOBAL MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 4 GLOBAL ISCHEMIC STROKE MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 5 GLOBAL ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023 ($ MILLION)
TABLE # 6 GLOBAL ELECTROCARDIOGRAM (ECG) MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 7 GLOBAL ECHOCARDIOGRAM MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 8 GLOBAL CHEST X-RAY MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 9 GLOBAL CARDIAC CATHETERIZATION MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 10 GLOBAL CORONARY ANGIOGRAM MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 11 GLOBAL ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
TABLE # 12 GLOBAL DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 13 GLOBAL SURGERY MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
TABLE # 14 GLOBAL ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLION)
TABLE # 15 NORTH AMERICA ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023 ($ MILLION)
TABLE # 16 NORTH AMERICA ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023 ($ MILLION)
TABLE # 17 NORTH AMERICA ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
TABLE # 18 NORTH AMERICA ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 19 EUROPE ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023 ($ MILLION)
TABLE # 20 EUROPE ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023 ($ MILLION)
TABLE # 21 EUROPE ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
TABLE # 22 EUROPE ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 23 ASIA-PACIFIC ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023 ($ MILLION)
TABLE # 24 ASIA-PACIFIC ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023 ($ MILLION)
TABLE # 25 ASIA-PACIFIC ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
TABLE # 26 ASIA-PACIFIC ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE # 27 ROW ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023 ($ MILLION)
TABLE # 28 ROW ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023 ($ MILLION)
TABLE # 29 ROW ISCHEMIC HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
LIST OF FIGURES
FIGURE # 1 GLOBAL ISCHEMIC HEART DISEASES MARKET SHARE BY DISEASE TYPE, 2017 VS 2023 (%)
FIGURE # 2 GLOBAL ISCHEMIC HEART DISEASES MARKET SHARE BY DIAGNOSIS METHOD, 2017 VS 2023 (%)
FIGURE # 3 GLOBAL ISCHEMIC HEART DISEASES MARKET SHARE BY TREATMENT, 2017 VS 2023 (%)
FIGURE # 4 GLOBAL ISCHEMIC HEART DISEASES MARKET SHARE BY GEOGRAPHY, 2017 VS 2023 (%)
FIGURE # 5 US ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 6 CANADA ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 7 UK ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 8 FRANCE ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 9 GERMANY ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 10 ITALY ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 11 SPAIN ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 12 ROE ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 13 INDIA ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 14 CHINA ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 15 JAPAN ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 16 REST OF ASIA-PACIFIC ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 17 ROW ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 1 GLOBAL ISCHEMIC HEART DISEASES MARKET SHARE BY DISEASE TYPE, 2017 VS 2023 (%)
FIGURE # 2 GLOBAL ISCHEMIC HEART DISEASES MARKET SHARE BY DIAGNOSIS METHOD, 2017 VS 2023 (%)
FIGURE # 3 GLOBAL ISCHEMIC HEART DISEASES MARKET SHARE BY TREATMENT, 2017 VS 2023 (%)
FIGURE # 4 GLOBAL ISCHEMIC HEART DISEASES MARKET SHARE BY GEOGRAPHY, 2017 VS 2023 (%)
FIGURE # 5 US ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 6 CANADA ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 7 UK ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 8 FRANCE ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 9 GERMANY ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 10 ITALY ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 11 SPAIN ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 12 ROE ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 13 INDIA ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 14 CHINA ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 15 JAPAN ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 16 REST OF ASIA-PACIFIC ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE # 17 ROW ISCHEMIC HEART DISEASES MARKET SIZE, 2017-2023 ($ MILLION)
